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Abstract
Tumor vaccines have held much promise, but to date have demonstrated little clinical suc-
cess. This lack of success is conceivably due to poor tumor antigen presentation combined
with immuno-suppressive mechanisms exploited by the tumor itself. Knock down of Inhibitor
of differentiation protein 2 (Id2-kd) in mouse neuroblastoma whole tumor cells rendered
these cells immunogenic. Id2-kd neuroblastoma (Neuro2a) cells (Id2-kd N2a) failed to grow
in most immune competent mice and these mice subsequently developed immunity against
further wild-type Neuro2a tumor cell challenge. Id2-kd N2a cells grew aggressively in
immune-compromised hosts, thereby establishing the immunogenicity of these cells. Ther-
apeutic vaccination with Id2-kd N2a cells alone suppressed tumor growth even in estab-
lished neuroblastoma tumors and when used in combination with immune checkpoint
blockade eradicated large established tumors. Mechanistically, immune cell depletion stud-
ies demonstrated that while CD8+ T cells are critical for antitumor immunity, CD4+ T cells
are also required to induce a sustained long-lasting helper effect. An increase in number of
CD8+ T-cells and enhanced production of interferon gamma (IFNγ) was observed in tumor
antigen stimulated splenocytes of vaccinated mice. More importantly, a massive influx of
cytotoxic CD8+ T-cells infiltrated the shrinking tumor following combined immunotherapy.
These findings show that down regulation of Id2 induced tumor cell immunity and in combi-
nation with checkpoint blockade produced a novel, potent, T-cell mediated tumor vaccine
strategy.
Introduction
Neuroblastoma accounts for 6% of all childhood cancers in the United States, with about 700
children younger than 15 diagnosed each year. It is the third most common tumor in child-
hood and the most common cancer in babies younger than one. High-risk patients with
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unfavorable tumors continue to have dismal prognosis despite aggressive multi-modal treatment
strategies [1–4]. To date, cancer vaccines have held much promise for therapy [5,6] but little
clinical success. Active immunity against high-risk neuroblastoma is difficult to demonstrate,
primarily due to large tumor bulk, rapid cellular proliferation and high-dose chemotherapy that
weaken the patient’s immune system. In addition, neuroblastoma builds a sophisticated immu-
nosuppressive microenvironment that prevents the development of effective T-cell immunity
[7–12]. Thus, the task of establishing an effective anti-tumor response in neuroblastoma is
daunting, considering the low immunogenicity of this high-risk tumor [13] along with tumor-
induced immune suppression [14] and evasion.
Using a mouse model of neuroblastoma we have described a novel paradigm in tumor biol-
ogy known as reversible adaptive plasticity [15] (RAP).RAP allows tumor cells to reversibly
transition between highly proliferative anchorage dependent and slow growing anoikis resis-
tant or anchorage independent phenotypes. This phenotypic heterogeneity is observed in
mouse and human neuroblastoma, as well as in many other high-risk tumor types suggesting
that RAP occurs during tumor growth and adaptation. A critical characteristic of RAP in
mouse neuroblastoma is the necessary and abundant expression of inhibitor of differentiation
protein 2 (Id2) in its anchorage dependent phenotype [16]. This is true for human neuroblas-
toma as well, in which we have described abundant Id protein expression. Of interest, Id pro-
teins can be reactivated in human cancer and it is proposed that deregulated Id signaling may
promote multiple attributes of malignant behavior [17]. The excessively high expression of Id
in anchorage dependent neuroblastoma cells and its function as an effector of n-myc make it
an important target in neuroblastoma [18,19]. To understand the role of Id2 in neuroblastoma
cell plasticity, we targeted Id2 expression in Neuro2a cells with lentiviral vectors expressing
Id2shRNA and found that Id2 is the key molecule modulating phenotypic transition in neuro-
blastoma [16].
In an attempt to determine the effect of knockdown of Id2 protein on tumorigenicity in
vivo, we implanted Id2 knock down Neuro2a (Id2-kdN2a) cells in mice. Unexpectedly, most of
the mice rejected the tumor cells, and subsequently were protected against further wild-
type tumor cell challenge. In contrast, when immune-deficient mice were challenged with
Id2-kdN2a cells the tumors grew aggressively. These findings show that down regulation of Id2
not only attenuates tumorigenicity of the neuroblastoma cells, but also renders the cells immu-
nogenic and induced host immunity.
Immunomodulatory antibodies that directly enhance the function of T-cells potentially
offer a means of overcoming immune escape mechanisms by generating effective antitumor
immunity [20–22]. In particular, mouse tumor models demonstrate that blockade of the check-
point protein, cytotoxic T lymphocyte antigen-4 (CTLA-4), a negative regulator of T cell
responses, augments immunity to tumor cells when used on its own or in combination with
other therapeutic interventions [6,23–25]. The combination of anti-CTLA-4 immunotherapy
with agents that prime immune response is illustrated in multiple tumor models and highlights
the importance of immune priming for successful anti-CTLA-4 immunotherapy. Synergistic
effects of anti-CTLA-4 antibodies are demonstrated in combination with vaccines in EL4 lym-
phoma [26], B16 melanoma [27], prostate cancer [28] and SM1 mammary carcinoma [29]
models suggesting that combination immunotherapy activates the immune system, sustains a
functional response and reverses tumor tolerance. Two antibodies that block CTLA-4, ipilimu-
mab and tremelimumab, have been evaluated in clinical trials. Ipilimumab is shown to signifi-
cantly prolong the overall survival of patients with metastatic melanoma [30,31] and is
approved by the United States Food and Drug Administration for the treatment of advanced
melanoma. Phase II trials of these blocking antibodies are underway in adult patients with met-
astatic colorectal, gastric and esophageal cancers and in non-small cell lung cancer [32,33].
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With the exception of a recent report suggesting CTLA-4 antibody combined with peptide
antigen as an effective immunotherapy against neuroblastoma [25], there is no preclinical data
on the role of immune-modulators in the treatment of neuroblastoma.
By exploiting the serendipitous finding that Id2-Kd N2a cells were immunogenic, we
vaccinated mice with Id2-Kd N2a cells in combination with anti-CTLA-4 antibody. This
combination vaccine strategy induced eradication of large established neuroblastoma tumors.
Moreover, immune cell depletion studies demonstrated that while CD8+ T-cells are absolutely
necessary for antitumor immunity, CD4+ T-cells are also required to induce a sustained long-
lasting helper effect. Finally, highly functional cytotoxic CD8+ T-cells infiltrated the shrinking
tumor microenvironment validating the role of T-cell immunity in this vaccine strategy. These




Female A/J, SCID and nude mice (6 weeks old) were purchased from Jackson Laboratory (Bar
Harbor, ME). The animals were acclimated for 4–5 days prior to tumor challenge. All proce-
dures were approved by the Institutional Animal Care and Use Committee of Children’s
National Medical Center, Washington DC.
Cells
Neuro2a is the murine neuroblastoma cell line derived from AJ mice and purchased from
ATCC (Manassas, VA). Cells were cultured as anchorage dependent in DMEM (Gibco, Carls-
bad, CA) containing 10% fetal bovine serum (FBS, Gibco) and 1% penicillin/streptomycin
(Sigma, St. Louis, MO). The aggressive subclone of Neuro2a (AgN2a) cells was produced by
repeated in vivo passaging of the cells as described previously [34].
Human neuroblastoma samples
De-identified fresh human neuroblastoma samples were obtained from the Pathology depart-
ment of CNMC. Written informed consents were obtained from the parents or guardians of
the patients in accordance with the Declaration of Helsinki. All procedures involving the use of
human tumor specimens were approved by the Institutional Review Board of CNMC.
Cell transductions
The anchorage dependent Neuro2a cells were transduced with Id2-shRNA expressing lentiviral
particles containing a Puromycin resistance gene (Santa Cruz Biotechnology, Santa Cruz, CA)
for stable knockdown of Id2. The stable clones expressing the Id2-shRNA (Id2kd N2a) were
selected using Puromycin according to the manufacturer’s instructions. Scrambled shRNA len-
tiviral particles were used as control and effective transfection of scrambled sh-RNA again was
proven with Puromycin selection similar to the Id2-kd clones. Untransfected controls did not
survive the Puromycin challenge. The knock down of Id2 was validated by western blot analy-
sis. Luciferase expressing Neuro2a cells were constructed by transducing the Neuro2a cells
with luciferase (firefly) expressing lentiviral particles (GenTarget Inc, San Diego, CA) and
selecting the clones with Puromycin. Luciferase expression was determined by measuring bio-
luminescence in a luminometer using the Luciferase Assay System (Promega, Madison, WI).
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Antibodies
Anti-CTLA-4 antibody (9D9) and mouse IgG2b isotype control were purchased from
BioXCell. Anti-rabbit Id2 antibody was purchased from Santa Cruz Biotechnology. Mouse
anti-CD4-APC, CD8α-PercP, CD45-FITC, purified mouse anti-CD8α, CD4, NK1.1 and CD3
antibodies and mouse regulatory T cell staining kits were purchased from eBioscience (San
Diego, CA).
Mouse neuroblastoma therapy models
The right flank of A/J mice were injected subcutaneously (s.c) with 1x106 freshly prepared
tumor (Neuro2a or AgN2a) cells in 100 μl PBS on day 0. One millionId2-kd N2a cells were
injected (s.c.) on their left flank on day 6 and again on day 13. The mice developed 5 mm size
tumors on their right flank by day 6. Anti-CTLA-4 antibody (150 μg per mouse) or equivalent
amount of IgG2b isotype control were administered intra-peritoneally (i.p.) on days 6, 9 and
12. Mice were monitored daily following tumor inoculation. Tumor growth was recorded on
alternate days by measuring the diameter in two dimensions using a caliper and by imaging the
mice for tumor bioluminescence using IVIS Lumina III (Perkin Elmer).Tumor volume was
calculated using the formula: (large diameter x small diameter)2 x 0.52. A tumor size of 20 mm
diameter in any dimension was designated as the endpoint and mice were euthanized at that
time. Euthanasia was achieved through cervical dislocation after CO2 narcosis. If the tumor
impaired mobility of the animal, became ulcerated or appeared infected, or the mice displayed
signs of “sick mouse posture” the mice were euthanized and removed from the study group.
Food was provided on the cage floor when the tumor size reached 15 mm in diameter. All the
procedures are approved by the IACUC at CNMC and are in accordance with the humane care
of research animals.
In vivo T cell depletion models
CD8/CD4/natural killer (NK) cells were depleted by i.p. administration of purified anti-CD8α
(100μg /mouse), CD4 (100μg /mouse) and NK1.1 (300μg /mouse) depletion antibodies starting
a day prior to Neuro2a cell inoculation and by repeating injections on days 3, 7, and 11 after
inoculation. Depletion of CD8+, CD4+ and NK1.1+ T-cells were validated using peripheral
blood and analyzed by flow cytometry (>95% depletion). All the mice in depletion studies
were subjected to Id2-kd N2a cell vaccination and CTLA-4 blockade as described above.
Tumor digestion
Mouse and human tumors were weighed, and minced in 2mL of serum free RPMI. Minced
tumors were placed in a 50mL tube, and filled to a final volume of 5mL serum free RPMI per
1g of tumor. Enzymatic digestion of tumors were performed with Collagenase I (Sigma), Dis-
pase II (Roche) and DNase I (Roche) used at a final concentration of 1500U/mL, 4.8mg/mL,
and 3000U/mL, respectively. The tumors were digested in a 37°C shaker bath for 20 minutes,
and then placed on ice for 1–2 minutes, allowing the remaining undigested pellet to settle. The
supernatant containing the single cell suspension was passed through a 40μm strainer, before
being centrifuged at 250 x g for 5 minutes, and finally resuspended at the desired volume.
Flow cytometry
Cells from mouse and human tumor digests and splenocytes were stained for CD4, CD8 and
CD45 using fluorochrome conjugated antibodies described above and flow cytometry was
A Novel, Potent Tumor Vaccine Strategy
PLOS ONE | DOI:10.1371/journal.pone.0129237 June 16, 2015 4 / 18
performed in a FACSCalibur (BD Biosciences, San Jose, CA). Data analysis was done using
FlowJo software (Tree Star, Inc., Ashland, OR).
Interferon-γ by ELISA
Spleen cells were harvested and 2x105cells were plated per well into 96-well round-bottom plates.
The spleen lymphocytes were stimulated with the following: 2x104 wild type Neuro2a cells, 2x104
Id2 knock down Neuro2a cells and 1.0 μg/mL of purified anti-CD3. Splenocytes were then
incubated at 37°C for 48 hours prior to IFN-γ assay. Cell culture supernatants were collected
from triplicate wells after stimulation and IFN-γ secreted by lymphocytes were measured by
ELISA using purified capture and biotinylated detection antibody pairs (BD Biosciences). The
ELISA plates were read using the EnSpire 2300 Multilabel Reader (Perkin Elmer, Shelton, CT) at
450 nm.
Chromium-51 release cytotoxicity assay
Cytotoxic T lymphocyte activity of tumor infiltrating lymphocytes was determined by stan-
dard 51Cr release assays. In brief, Neuro2a cells (target) were incubated with 0.2 mCi Na[51]
CrO4 for 45 min at 37°C. Cells were washed twice with complete medium and transferred
to round-bottom 96-well plates at 5 × 103 cells/well. CD8+ T-cells (effector) were purified
from the unvaccinated growing and vaccinated shrinking total tumor digest using the
MACS cell separation system (Miltenyi Biotec, Auburn, CA). Due to low abundance of the
infiltrating lymphocytes in the growing tumors, purified T-cells were pooled together from
four unvaccinated growing tumors for the assay. Effector T-cells were added to target tumor
cells at varying numbers in a final volume of 0.2 ml to give the effector:target ratios as
indicated in the Figure legends. After 4 hours incubation at 37°C, 0.1 ml of supernatant was
harvested, and released radiolabel was determined by scintillation counting. Maximal release
from targets was determined by treatment of cells with 1% Triton X-100, spontaneous release
was determined from cultures of labeled targets incubated with medium only, and the
formula used for determination of specific lysis was: [(experimental release − spontaneous
release)/(maximal release − spontaneous release)] × 100.
Statistical analysis
The two-tailed Student’s t-test was used to determine statistical significance between groups
unless otherwise stated. A probability level of p<0.05 was considered to be statistically
significant.
Results
Knock down of inhibitor of differentiation protein 2 (Id2) attenuates
neuroblastoma tumor cells and induces host immunity
We recently described that targeting Id2 expression in anchorage dependent Neuro2a cells
reduced their proliferation, increased the rate of tumorsphere formation and activated tyrosine
kinase and TGFβ signaling pathways [16]. In an attempt to determine the effect of Id2 down-
regulation on Neuro2a tumorigenicity and adaptive transition in vivo, we knocked down Id2
with lentiviral vectors expressing Id2 shRNA in neuro2a cells. The knock down was confirmed
by western blot analysis of Id2 protein expression [16]. Implantation of Id2-kd N2a cells sur-
prisingly resulted in tumor rejection in 60% of mice (Figs 1A and 2B) and these mice were sub-
sequently protected against further wild-type Neuro2a tumor cell challenge (Fig 1B). In
contrast, severe combined immune-deficient (SCID) and nude mice grew Id2-kd tumors
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aggressively (Fig 1C), highlighting the immunogenicity of the Id2-kd cells. The tumorigenicity
of scrambled shRNA lentivirus transfected Neuro2a cells (sc-shRNA-N2a) was comparable to
the wild-type cells (Fig 1A). These findings suggest that down regulation of Id2 not only atten-
uates tumorigenicity in the mouse model, but also induced host immunity indicating the
potential role of Id2-kd N2a cells as an antigenic vehicle for an attenuated, whole tumor cell
vaccine.
To this end, we tested the use of Id2-kd N2a cells in a therapeutic treatment model of estab-
lished neuroblastoma tumor. Id2-kd N2a cells were vaccinated into the left leg of mice, three
days following inoculation of wild type Neuro2a tumor cells in the right leg, and tumor growth
was monitored. None of the mice developed tumor at the site of Id2-kd N2a cell injection,
while the growth of wild type tumor on the opposite leg was delayed when compared to control
unvaccinated mice (Fig 1D). In contrast, when wild type cells were injected into both hind legs
5 days apart, tumors grew aggressively on both sides, suggesting the absence of concomitant
immunity in the wild type Neuro2a, validating the immunogenicity and potential use of Id2-kd
N2a cells as a tumor vaccine.
Fig 1. Id2 knock down attenuates tumorigenicity and induces host immunity. (A) Sixty percent of mice (n = 9/15) challenged (right leg) with Id2 knock
down Neuro2a (Id2kdN2a) cells rejected tumor and survived tumor-free, whereas all mice challenged with either wild type Neuro2a (wtN2a, n = 20) or
scrambled shRNA lentivirus transfected Neuro2a (sc-shRNA-N2a, n = 5)) cells died from tumor burden. (B) Tumor free survivors from (A) were re-
challenged with wtN2a cells into their left leg 6 weeks after they cleared the tumor and 8 out of 9 mice were protected from tumor growth. (C) SCID and nude
mice grew tumors aggressively following inoculation with Id2kdN2a cells. (D) Following inoculation of wtN2a cells in the right leg, Id2kdN2a (n = 10) and
wtN2a (n = 5) cells were vaccinated into the left leg of mice, 3 and 5 days later respectively. The wild type tumor growth on the right leg was delayed in
Id2kdN2a vaccinated mice when compared to control unvaccinated mice or wtN2a vaccinated mice.
doi:10.1371/journal.pone.0129237.g001
A Novel, Potent Tumor Vaccine Strategy
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CTLA-4 blockade enhances anti-tumor immunity induced by Id2 knock
down neuroblastoma cells
In order to determine if the therapeutic effect of the Id2-kd N2a whole tumor cell vaccine
could be enhanced, we elected to combine this therapy with immune checkpoint blockade in
the form of anti-cytotoxic T lymphocyte associated antigen 4 (CTLA-4) antibody. Indeed, in a
prophylactic tumor vaccination model (Fig 2A) we observed that CTLA-4 blockade started on
day 5 after Id2-kd N2a cell implantation resulted in 100% tumor rejection (Fig 2D) in contrast
to 80% when given on the same day as the Id2-kd N2a cells (Fig 2C and 2D) highlighting the
synergy between immune priming and immune modulation that is required for effective
tumor vaccine therapy. Moreover, all tumor-rejected mice developed complete immunity
against wild type tumor cells challenged 6 weeks after tumor clearance (Fig 2E).
Encouraged by the effectiveness of this prophylactic model, we reasoned that the combina-
tion of the Id2-kd N2a vaccine platform with anti-CTLA-4 antibody may break tolerance even
in the presence of large established tumors and induce potent T-cell immunity. We thus exam-
ined the combined vaccine/immunotherapy effect in an established neuroblastoma tumor
model (Fig 3A). Combined therapy eradicated 60% of established Neuro2a tumors in the wild-
type model (Fig 3B) and 90% in AgN2a (aggressive non-immunogenic) model (Figs 3C, 4A
and 4B), whereas, CTLA-4 blockade alone resulted in 40% tumor regression in the Neuro2a
model and had no effect on tumor growth in the AgN2a model (Fig 3B and 3C). Of interest,
again none of the mice developed tumor at the site of Id2-kd N2a cell injection in this estab-
lished tumor model.
Irradiation of Id2-kd N2a whole tumor cells does not impair
immunogenicity
Live attenuated vaccines induce long-lived cellular and humoral immunity, but safety concerns
limit their utilization. Inactivation and attenuation of pathogens have been strategies for vac-
cine development since the advent of vaccination [35]. Therefore, in lieu of the potential risk of
live albeit attenuated Id2-kd N2a tumor cells we sought to determine whether irradiation of
these cells would dampen the effects of this tumor cell vaccine strategy. We subsequently tested
irradiated (35 Gray) Id2-kd N2a cells as a whole tumor cell vaccine antigen source in combina-
tion with anti-CTLA-4 antibody against AgN2a (Fig 3A) and found that 60% of mice eradi-
cated established tumors (Fig 4D). In contrast, irradiated wild type Neuro2a cells administered
in a similar combination fashion, had no effect on growth of the AgN2a aggressive tumor cells
(Fig 4C). This observation again supports the antigenicity of Id2-kd N2a cells for vaccination,
but is also encouraging in that irradiation extends the margin of vaccine safety. Although irra-
diation of tumor cell vaccines is known to evoke potent anti-tumor immunity in melanoma
and lung cancer models [36,37], we find neither a favorable nor particularly adverse effect of
irradiation on the antigenic properties of the Id2-kd cells in neuroblastoma. Taken together
these results suggest that Id2-kd N2a cells provide a safe and effective source of tumor antige-
nicity and in combination with checkpoint blockade induce potent tumor immunity.
CD8+ T-cells are necessary and CD4+ T-cells are required for
neuroblastoma tumor eradication
To explore which immune effector cells are critical for eradicating the established tumors fol-
lowing combined vaccine therapy, we depleted specific T cell subsets by systemic administra-
tion of antibodies against CD4, CD8 and Natural Killer (NK) cells. In vivo depletion of cell
phenotypes was confirmed by blood sampling. Depletion of CD8+ T-cells completely
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abrogated the therapeutic effect of combined Id2-kd N2a cells and anti-CTLA-4 antibody (Fig
5A). Interestingly, all CD8+ T cell depleted mice also developed tumors at the site of Id2-kd
N2a cell vaccination (Fig 5B), again demonstrating the importance of intact immunity. Mice
lacking NK cells were for the most part able to reject their tumors following therapy (Fig 5A).
Fig 2. CTLA-4antibody enhances anti-tumor effect of Id2-kd N2a cell vaccine in prophylactic tumor models. (A) Schematic diagram of the
prophylactic Neuro2a tumor models. Two models (0-day and 5-day) were tested, in which three doses of α-CTLA4 antibody were administered either days
0,3,6 or 5,8,11 following Id2kdN2a cell inoculation into the right leg of the mice (n = 5 for each model). (B, C) Tumor growth curves show that 60% of mice
challenged with only Id2-kd N2a cells (no α-CTLA4) survived tumor free (B) and in the 0-day model (C) 40% of mice never grew tumor and another 40%
cleared the tumor slowly and became tumor free. Graph depicts tumor growth in individual mice. The parenthesis indicates number of mice that survived
tumor free. (D) All mice in the 5-day model survived tumor free, in contrast to 80% in the 0-day model or 60% in the Id2kd cells model. (E) Six weeks after
tumor clearance, the tumor-free mice from (B) (n = 9) were re-challenged with wtN2a cells into their left leg and 100%were completely immunized against
wild type tumor growth. Only 1 of 5 mice (20%) treated previously with anti-CTLA4 antibody alone survived tumor free after wtN2a challenge at 6 weeks.
doi:10.1371/journal.pone.0129237.g002
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CD4+ T cell depletion initially had minimal adverse effect on the therapeutic vaccine strategy
and 75% of mice lacking CD4+ T-cells remained tumor free for 4 weeks. Interestingly, all mice
in the CD4 depletion group eventually developed delayed tumors, after the 4 week period (Fig
5A). To determine if re-accumulation of CD4+ regulatory T-cells (Treg) cells played a role in
tumor relapse, cell infiltrates from the tumors of CD4 depleted mice were stained with anti-
CD45, CD4 and FoxP3 antibodies. No evidence of Treg cell infiltrate (Fig 5C) was identified;
indicating that tumor relapse in CD4+ T cell depleted mice is not mediated by the late accumu-
lation of Treg cells. The most likely explanation is that depletion of CD4+ T-cells during com-
bined immunotherapy failed to help with activation of cytotoxic CD8+ T-cells resulting in
inadequate immunity. Inadequate immunity is shown by the need of CD4 help to obtain com-
plete activation of CD8 cytotoxic T-cells. Taken together, these results suggest that both CD4
+ and CD8+ T-cells are required for immunity and effective tumor cell elimination following
combination immunotherapy.
Fig 3. Combination of Id2kd N2a and α-CTLA4 antibody as a therapeutic vaccine. (A) Schematic diagram of the therapeutic vaccine strategy. Two
established tumor models, namely Neuro2a (wtN2a) and AgN2a were tested, where mice challenged with either wtN2a or AgN2a cells were subjected to a
combination immunotherapy with Id2kdN2a and α-CTLA4 antibody starting at day 6 after inoculation. Neuroblastoma tumors are normally visible (5mm in
diameter) in AJ mice by day 6. Tumor growth curves in individual mice of wtN2a (B) and AgN2a (C) cells show that the Id2kd tumor cell vaccination combined
with immune-modulation cures mice with established tumor. Parentheses indicate the number of mice that survived tumor free.
doi:10.1371/journal.pone.0129237.g003
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Robust T-cell immunity mediates tumor rejection in both mouse and
human neuroblastoma
The prior studies clearly describe indirect evidence for T-cell immunity as a mechanism of
tumor rejection following Id2-kd/checkpoint blockade therapy. We thus sought to define the
in vivo cellular response in mice that cleared tumor following combination therapy. Splenic
CD8+ T cell counts were significantly higher in mice that were vaccinated and cleared tumor,
compared to naïve mice that were not vaccinated nor challenged with tumor (Fig 6A and 6B).
The production of IFNγ from T-cells is a hallmark of immune cell response, thus we measured
IFNγ secretion from splenocytes following antigen stimulation. The splenocytes of mice that
cleared tumor secreted significant amounts of IFNγ following stimulation with wild type Neu-
ro2a or Id2kd N2a cells (Fig 6C) compared to splenocytes taken from naïve mice.
To gain more insight into the mechanism of tumor cell rejection, we investigated the micro-
environment of shrinking mouse tumors by quantifying tumor infiltrating lymphocytes (TIL)
following vaccination. TIL are frequently found in tumors and are effective at delaying tumor
progression suggesting the potential influence of immune cell infiltrates on patient prognosis
[38–41]. We found a massive increase in CD45+ cells as well as a robust infiltration of CD8
+ T-cells in the shrinking tumors following combination immunotherapy (Fig 6D–6F). To
elucidate the effector function of the TIL, freshly isolated and purified tumor infiltrating
CD8+ T-cells were subjected to standard chromium51 release assay. CD8+ TIL exhibited
potent cytotoxic activity against wild type Neuro2a cells without ex vivo recovery (Fig 6G).
This finding indicates the high functionality of these cells and further emphasizes the key role
that CD8+ T-cells play in inducing effective immunity and tumor regression.
Fig 4. Tumor clearance and effect of irradiation on tumor cell immunogenicity. (A, B) Representative mouse from untreated and combination therapy
group showing growing and shrinking tumor respectively. All bio-luminescent images were analyzed under the same scale.(C, D) Irradiated Id2 knock down
Neuro2a (IR-Id2kdN2a, n = 5) and wild type Neuro2a (IR-wtN2a, n = 5) were compared as whole tumor cell vaccine antigen source in combination with α-
CTLA-4 antibody against AgN2a (see Fig 3A). IR-Id2kdN2a vaccine was able to eradicate 60% of tumors in comparison to IR-wtN2a cells which had no effect
on growth of the AgN2a tumors. All mice in (C) were sacrificed on day 20 due to large tumor burden. The parenthesis indicates number of mice that survived
tumor free.
doi:10.1371/journal.pone.0129237.g004
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As a clinical correlate of T cell immunity in neuroblastoma we examined freshly harvested
human tumor specimens for TIL presence. We observed minimal CD8+ cells in several tumors
with poor prognosis (0 to 1.3% of tumor lymphocytes) (n = 3), whereas in neuroblastoma
tumors from patients with Opsoclonus Myoclonus Syndrome (OMS) (n = 2) a robust infiltra-
tion of CD8+ cells was noted (15.4 and 17.3% of tumor lymphocytes) (Fig 7A and 7B). It is
now well documented that although childhood neuroblastoma carries a significant mortality
rate, neuroblastomas associated with OMS tend to be low grade and have a significantly more
favorable outcome [42–44].
Fig 5. T cell immunity required for tumor eradication following combination therapy.Mice were depleted of specific T cell subsets by systemic
administration of antibodies against CD4, CD8 and NK cells and subjected to combined Id2kdN2a cells and α-CTLA-4 antibody treatment strategy (see Fig
3A) (A) In vivo depletion of CD4+, CD8+ and NK+ cells (n = 5 for all groups) shows that the therapeutic effect of the combined treatment was completely
abrogated by CD8+ cell depletion. Mice lacking NK cells were for the most part able to reject their tumors following therapy. CD4+ T cell depletion initially
appeared to have minimal adverse effects on the therapeutic vaccine strategy, but after 4 weeks all mice in the CD4 depletion group developed delayed
tumors. (B) All CD8+ T cell depleted mice developed tumors at the site of Id2kdN2a cell vaccination as well. (C) Cell infiltrates from the tumors of CD4
depleted mice were stained with anti-CD45-FITC, CD4-APC and FoxP3-PerCPCy5.5 antibodies to identify Treg cells; there was no evidence of Treg cell
infiltrate in the late developing tumors from CD4 depleted mice. Purified Treg cells were used as positive control.
doi:10.1371/journal.pone.0129237.g005
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Fig 6. Enhanced in vivo immune responsemediates tumor clearance. (A) Representative flow cytometry plots showingCD4+ and CD8+ T-cells in CD45
+ splenocytes of naïve (n = 5), tumor bearing (n = 3) and tumor free (n = 5) mice. (B) Graphical representation of (A) indicating significant (** p = 0.013)
increase in CD8+ cells in the spleens of mice cleared of tumor. (C) Splenocytes of mice that cleared tumor had enhanced IFNγ secretion following stimulation
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Discussion
The ability of cancer cells to escape immune surveillance is a common hallmark of cancers
with poor prognosis [45]. Neuroblastoma is an example of a tumor with high-risk stratifica-
tion, frequently exhibiting a poor prognosis and recurrent disease following initial therapy.
Unlike several other childhood solid tumors, successful treatment of high-risk neuroblastoma
remains a major challenge with limited effective therapeutic options. Strategies to circumvent
treatment failures are intensively studied and amongst these strategies, immunotherapy has
attracted much attention. Our current results offer a novel pre-clinical strategy combining tar-
geted gene knock down and checkpoint blockade as a potent, effective, tumor-specific vaccine
with CD3 (* p<0.02),wtN2a or Id2kdN2a cells (*** p<0.0001). (D) Remarkable increase in CD45+ cells detected in the shrinking tumor.(E, F) Tumor
infiltrating lymphocytes (TIL) following vaccination were quantified and a massive infiltration of CD8+ T-cells was detected in the shrinking tumors (n = 5) as
opposed to the growing tumors (* p<0.02). (G) Chromium51 release assay exhibited potent cytotoxic activity of CD8+ TIL from shrinking tumor (n = 3);
whereas the TIL isolated from growing tumors (n = 4) show no activity at all. Data presented as mean ± S.D.
doi:10.1371/journal.pone.0129237.g006
Fig 7. TIL in human neuroblastoma samples. Five freshly harvested human neuroblastoma specimens
were analyzed for TIL; two of the tumors were from patients with Opsoclonus/myoclonus syndrome (OMS).
(A) Representative flow cytometry plots showing CD4+ and CD8+ T-cell population in the neuroblastoma
tumor lymphocytes. (B) Graphical representation of (A) indicating a remarkable infiltration of CD8+ T-cells in
the two tumors associated with OMS (NB-OMS) as opposed to the other three neuroblastoma (NB) tumors
that had minimal TIL.
doi:10.1371/journal.pone.0129237.g007
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strategy for neuroblastoma. This strategy is dependent on a robust cytotoxic CD8+ T lympho-
cyte (CTL) response that is supported by CD4+ T helper cells for tumor eradication.
Recent advances in the understanding of mechanisms regulating T-cell activation have made
significant progress in cancer immunotherapy. The activation state of the innate immune system
is thought to play a critical role in either the induction of immunity or tolerance after encounter-
ing tumor antigen. In contrast to the considerable literature documenting immunological
responses to melanoma in humans and in mouse models, there is a scarcity of data concerning
immunological responses to neuroblastoma. Based on present concepts of immunogenicity, it
comes as a surprise that live tumor cells induce an immune response at all. The whole tumor cell
vaccine studied in this work, contains no pathogen associated molecular patterns nor artificial
inflammatory cytokines; yet potent immunogenicity is attained by targeting a key molecule of
reversible adaptive plasticity. Id2-kd N2a cells induced immunity in a syngeneic immune-
competent mouse model, yet these tumor cells grew unabated in immune-compromised hosts.
In the immune competent host, long-term immunity was induced against subsequent wild-
type tumor challenge and of clinical interest; immunogenicity of the knock-down cells was main-
tained following irradiation. The mechanism of tumor cell immunogenicity in Id2-kd cells is
unknown, but is clearly a perturbation in molecular homeostasis of the tumor cells. Changes
induced by targeting Id2 in the tumor cell could vary from increased antigenicity, enhanced anti-
gen presenting cell uptake or loss of immune-suppressive or immune-evasive mechanisms. Four
Id proteins (Id1, Id2, Id3 and Id4) are described [46], and may function in a redundant manner.
We targeted Id2 in the mouse neuroblastoma cell line, as this was the most dominant and differ-
entially expressed protein (~20 fold) between the anchorage dependent and independent cell
phenotypes [16]. In other mouse and human tumor cell lines Id2 was not dominant whereas Id1
and/or Id3 were (unpublished data). Id1 and/or Id3 may be better targets in other cancer types
for inducing the attenuated, immunogenic effect observed following Id2 knock down in Neuro2a
cells. The effects described with Id2 targeting may or may not be expanded to other cell lines;
research to determine applicability of this whole tumor cell vaccine strategy for other tumor
types is underway.
Despite the presence of tumor associated antigens, tumor growth enhances antigen specific
expansion of Treg inducing tumor tolerance [47,48]. Similarly, vaccination alone can induce
limited immunity with expansion of regulatory T-cells or by inhibition of T-cell activation.
Treatment with monoclonal antibody specific for cytotoxic T lymphocyte associated antigen-4
(CTLA-4), a checkpoint protein expressed on T-lymphocytes has emerged as an effective can-
cer therapy. The effect is most likely induced by both enhancing T-cell expansion and/or by
selective Treg depletion within the tumor mass [49,50].
Immune checkpoint modulation has become a clinically relevant therapy approach in mela-
noma and lung cancer [27,51,52]; in particular, anti-CTLA-4 antibody shows promising results
in clinical trials in melanoma patients [30,31]. Like melanoma, neuroblastoma is derived from
neural crest stem cells and shares common antigenic determinants [53]. A phase I clinical trial
is underway for resistant tumors in children and adolescents using anti-CTLA4 antibody.
Although there is clear evidence that targeting checkpoint receptors activates endogenous anti-
tumor immunity with clinical benefit, the question of how checkpoint efficacy can be further
improved through rational combination therapies is essential. Our current pre-clinical results
provide a convincing treatment option, in which the combination of Id2kd neuroblastoma
tumor cells and CTLA-4 antibody prime a functional tumor-specific T cell response, increase
immune cell access to the tumor site, enhance anti-tumor immune cell function and eradicate
significant tumor burden. Our data in this primary tumor model indicates a synergy between
CTLA-4 blockade and Id2-kd N2a cells. Mice treated with either the altered cells or antibody
alone in the non-immunogenic aggressive tumor model had either marginal or no reduction in
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tumor growth, whereas the combination of both resulted in significant tumor clearance. This
suggests that an additional source of antigen from the cell-based vaccine contributes to T-
cell priming, which is enhanced by blockade of CTLA-4 mediated inhibitory signals of T-
cell activation. The ideal timing of combination vaccination and checkpoint blockade adminis-
tration is uncertain, but we observed improved cell rejection when anti-CTLA-4 antibody
administration lagged several days behind Id2-kd N2a cell implantation. This finding suggests
that a critical window exists in which antigen processing occurs prior to checkpoint blockade.
Our results show that the vaccine’s tumor ablative effect requires both CD8+ and CD4+ T-
cells. The immune cell depletion study proves that cytotoxic CD8+ T-cells (CTL) are indis-
pensable for tumor rejection, but also demonstrates the requirement for CD4+ T cell help for
effective induction of the CD8+ CTL response. Furthermore, we demonstrate a massive influx
of activated CD8+ CTL in regressing mouse tumors as was also observed in two human neuro-
blastomas associated with Opsoclonus Myoclonus Syndrome (OMS). A large body of evidence
has uncovered a correlation between the presence of lymphocyte infiltration and the survival of
patients affected by many types of cancer including neuroblastoma [39,41,54,55]. In particular,
presence of CD8+ T-cells was associated with a favorable prognosis [54,56] and is considered
the major component of an effective immune response to most tumors. Evidence suggests chil-
dren with coincident OMS and neuroblastoma have favorable outcome and become long-
term survivors [42–44]. Moreover, similar to our finding, diffuse and extensive lymphocytic
infiltration was observed in neuroblastic tumors associated with OMS [57] suggesting the role
of immune surveillance in recognizing and eradicating unfavorable tumor cells in these
patients.
The opsoclonus and myoclonus observed in this form of favorable OMS neuroblastoma is
probably a secondary autoimmune response to tumor immunity. Despite the often rapid,
potent and complete tumor rejection observed in our pre-clinical study, the mice remained
well and showed no signs of illness in the form of potential autoimmunity. Although no spe-
cific testing was undertaken to evaluate immune related adverse events (irAEs) in the animals,
they looked well and were followed for months following therapy. It is possible that the altered
whole tumor cell vaccine preferentially targets tumor-specific antigens as opposed to tumor-
related antigens, but this postulation is speculative as the actual antigen targets are unknown.
Although it is described that the threshold of inducing auto-immunity is lower than that of
producing tumor immunity [58], the well-being of the mice in this model is reassuring, but fur-
ther investigation prior to clinical translation is needed.
In conclusion, the work presented demonstrates that an attenuated Id2-kd whole neuroblas-
toma cell vaccine is safe in mice; induces broad tumor-specific cellular immunity, protects
against tumor formation in prophylactic tumor models and in combination with the clinically
relevant checkpoint immune modulator CTLA-4 antibody, eradicates large established neuro-
blastoma tumors. This work should enable translation of our findings into a therapeutic
patient-specific vaccine for resistant neuroblastoma tumors. The data also provide compelling
evidence for the development of potent tumor specific vaccine strategies, based on the combi-
nation of targeted gene knock down in tumor cells and checkpoint immune-modulation for
other aggressive high-risk solid tumors.
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